Women's health: making cardiovascular disease realWei, Janet; Shufelt, Chrisandra; Bairey Merz, C. NoelCurrent Opinion in Cardiology: September 2018 - Volume 33 - Issue 5 - p 506–513 doi: 10.1097/HCO.0000000000000544 PREVENTION: Edited by Andrew Pipe Abstract Author InformationAuthors Article MetricsMetrics Purpose of review When patients are seen for persistent chest pain in the absence of obstructive coronary artery disease, the physician must decide if the symptoms are due to myocardial ischemia in order to guide treatment. Recent findings Recent findings indicate that ischemia due to coronary microvascular dysfunction (CMD) is associated with subclinical coronary atherosclerosis and an adverse prognosis. Therapeutic probe trials suggest that antiatherosclerotic and anti-ischemic therapeutic strategies may be useful. A large randomized clinical trial of high-intensity statin, maximally tolerated angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker and low-dose aspirin (WARRIOR NCT#03417388) is in progress. Summary The diagnosis of CMD should be considered in patients with persistent angina, evidence of myocardial ischemia and normal coronary angiogram. Because of the associated adverse prognosis of CMD , conservative empiric treatment or further diagnostic evaluation of the coronary microvasculature can be performed. Diagnosis involves the measurement of coronary blood blow in response to a vasodilator agent invasively or noninvasively. Treatment of CMD can include the use of traditional antianginal and antiatherosclerotic medications. Clinical trials are needed to assess therapeutic strategies on the outcomes of cardiovascular disease and quality of life, in order to develop evidence-based guidelines. Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California, USA Correspondence to C. Noel Bairey Merz, MD, FAHA, FACC, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, 127 S. San Vicente Blvd, Suite A3206, Los Angeles, CA 90048, USA. Tel: +1 310 423 9680; fax: +1 310 423 9681; e-mail: Noel.BaireyMerz@cshs.org Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.